Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13184392 | 0.68 | CYP2A13 (0.40) | HRH3KMT2ACXCR4CYP2A13 | |
| SCHEMBL28767868 | 0.68 | POLB (0.37) | HRH3POLBKMT2A | |
| SCHEMBL22849925 | 0.66 | MAPT (0.48) | HRH3MAPTKMT2AKCNH2LRRK2 | |
| SCHEMBL21961418 | 0.66 | SMN1; SMN2 (0.42) | SMN1; SMN2HRH3MAPTPOLBKMT2A | |
| SCHEMBL22057200 | 0.65 | LRRK2 (0.38) | SMN1; SMN2HRH3MAPTPOLBKCNH2 | |
| SCHEMBL17076899 | 0.64 | HRH3 (0.44) | HRH3MAPTPOLB | |
| SCHEMBL15650979 | 0.64 | HRH3 (0.44) | SMN1; SMN2HRH3MAPTPOLBKCNH2 | |
| SCHEMBL28739179 | 0.63 | POLB (0.43) | SMN1; SMN2HRH3MAPTPOLBKCNH2 | |
| SCHEMBL3177451 | 0.63 | SMN1; SMN2 (0.46) | SMN1; SMN2CXCR4PTPN1 | |
| SCHEMBL10848052 | 0.62 | MAPT (0.72) | SMN1; SMN2HRH3MAPTKMT2AHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817379-A2 | PYRAZOLE AZOMETHINES AND COLORANTS CONTAINING THESE COMPOUNDS | The Procter and Gamble Company (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070033742-A1 | Pyrazole azomethines and colorants containing these compounds | PROCTER & GAMBLE COMPANY, THE | 2007-02-15 | — | — | US | disclosed |
| WO-2006060564-A2 | PYRAZOLE AZOMETHINES AND COLORANTS CONTAINING THESE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070033742-A1 | Pyrazole azomethines and colorants containing these compounds | KRT18, NOX5, TUBB3 | SMN1; SMN2 4744/4885HRH3 2343/4885MAPT 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.